Long-Term Treatment with n-3 Polyunsaturated Fatty Acids as a Monotherapy in Children with Nonalcoholic Fatty Liver Disease

Basit Öğe Kaydı
dc.authoridDundar, Bumin N/0000-0002-7506-061X|Hatipoglu, Nihal/0000-0002-0991-6539;
dc.contributor.authorBoyraz, Mehmet
dc.contributor.authorPirgon, Ozgur
dc.contributor.authorDundar, Bumin
dc.contributor.authorCekmez, Ferhat
dc.contributor.authorHatipoglu, Nihal
dc.date.accessioned2025-10-24T18:09:58Z
dc.date.available2025-10-24T18:09:58Z
dc.date.issued2015
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractObjective: To investigate the efficacy and safety of n-3 polyunsaturated fatty acids (PUFA) treatment in obese children with nonalcoholic fatty liver disease (NAFLD). Methods: One hundred and eight obese (body mass index (BMI) >95th percentile for age and sex) adolescents with NAFLD were included in the study. Mean age of the subjects was 13.8 +/- 3.9 years (9-17 yrs). The diagnosis of NAFLD was based on the presence of liver steatosis with high transaminases. The subjects were randomly divided into two groups. Group 1 (PUFA group, n=52) received a 1000 mg dose of PUFA once daily for 12 months and lifestyle intervention. Group 2 (placebo group, n=56) received a recommended diet plus placebo and lifestyle intervention for 12 months. Insulin resistance was evaluated by homeostasis model assessment of insulin resistance (HOMA-IR) from fasting samples. Results: BMI, fasting insulin levels and HOMA-IR values in both groups decreased significantly at the end of the study. In group 1, 67.8% of the patients had a decrease from baseline in the prevalence of steatosis (p<0.001). Frequency of elevated alanine aminotransferase (ALT) levels (39.2% to 14.2%; p<0.01) and elevated aspartate aminotransferase (AST) levels (25% to 17.8%; p=0.01) decreased significantly in the PUFA group. Following a 12-month diet plus placebo and lifestyle intervention treatment, 40.3% (21) of the patients in the placebo group also showed a decrease in frequency of steatosis (p=0.04) and slight decreases in frequency of elevated ALT levels (38.4% to 28.8%; p=0.01) and AST levels (30.7% to 28.8%; p>0.05). Conclusion: Our results indicated that n-3 PUFA treatment is safe and efficacious in obese children with NAFLD and can improve ultrasonographic findings and the elevated transaminase levels.
dc.identifier.doi10.4274/jcrpe.1749
dc.identifier.endpage127
dc.identifier.issn1308-5727
dc.identifier.issn1308-5735
dc.identifier.issue2
dc.identifier.pmid26316434
dc.identifier.scopus2-s2.0-84930429781
dc.identifier.scopusqualityQ2
dc.identifier.startpage121
dc.identifier.trdizinid199114
dc.identifier.urihttps://doi.org/10.4274/jcrpe.1749
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/199114
dc.identifier.urihttps://hdl.handle.net/20.500.12899/3913
dc.identifier.volume7
dc.identifier.wosWOS:000355936400006
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.publisherGalenos Yayincilik
dc.relation.ispartofJournal Of Clinical Research In Pediatric Endocrinology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20251023
dc.subjectNonalcoholic fatty liver disease; n-3 polyunsaturated fatty acids; adolescent; obesity; insulin sensitivity
dc.titleLong-Term Treatment with n-3 Polyunsaturated Fatty Acids as a Monotherapy in Children with Nonalcoholic Fatty Liver Disease
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu